These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 9632290)

  • 1. Quality assurance of the EORTC radiotherapy trial 22931 for head and neck carcinomas: the dummy run.
    Valley JF; Bernier J; Tercier PA; Fogliata-Cozzi A; Rosset A; Garavaglia G; Mirimanoff RO
    Radiother Oncol; 1998 Apr; 47(1):37-44. PubMed ID: 9632290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality assurance of the 22961 EORTC trial. A phase III study of the optimal combination of hormonal adjuvant treatment by LHRH analogue and radiation therapy for the management of locally advanced prostate cancer: the dummy run.
    Kouloulias VE; Giraud JY; Davis BJ; Dusserre A; Zurlo A; Bolla M
    Radiother Oncol; 2004 Oct; 73(1):11-20. PubMed ID: 15465141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality assurance for the EORTC 22071-26071 study: dummy run prospective analysis.
    Fairchild A; Langendijk JA; Nuyts S; Scrase C; Tomsej M; Schuring D; Gulyban A; Ghosh S; Weber DC; Budach W
    Radiat Oncol; 2014 Nov; 9():248. PubMed ID: 25424399
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality assurance for a multicenter Phase II study of stereotactic ablative radiotherapy for hepatocellular carcinoma ≤5 cm: a planning dummy run.
    Bae SH; Kim MS; Jang WI; Kim KB; Cho KH; Kim WC; Lee CY; Kim ES; Choi CW; Chang AR; Jo S; Kim JY
    Jpn J Clin Oncol; 2017 Jun; 47(6):535-542. PubMed ID: 28419246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality assurance of radiotherapy in the ongoing EORTC 1219-DAHANCA-29 trial for HPV/p16 negative squamous cell carcinoma of the head and neck: Results of the benchmark case procedure.
    Christiaens M; Collette S; Overgaard J; Gregoire V; Kazmierska J; Castadot P; Giralt J; Grant W; Tomsej M; Bar-Deroma R; Monti AF; Hurkmans CW; Weber DC
    Radiother Oncol; 2017 Jun; 123(3):424-430. PubMed ID: 28478912
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality assurance of the PREOPANC trial (2012-003181-40) for preoperative radiochemotherapy in pancreatic cancer : The dummy run.
    Versteijne E; Lens E; van der Horst A; Bel A; Visser J; Punt CJA; Suker M; van Eijck CHJ; van Tienhoven G
    Strahlenther Onkol; 2017 Aug; 193(8):630-638. PubMed ID: 28608305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality assurance in preoperative radiotherapy of rectal cancer: evaluation of a pre-trial dummy-run.
    Widder J; Sedlmayer F; Stanek C; Pötter R
    Radiother Oncol; 2000 Sep; 56(3):341-7. PubMed ID: 10974384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality assurance of the EORTC radiotherapy trial 22863 for prostatic cancer: the dummy run.
    Dusserre A; Garavaglia G; Giraud JY; Bolla M
    Radiother Oncol; 1995 Sep; 36(3):229-34. PubMed ID: 8532911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality assurance of axillary radiotherapy in the EORTC AMAROS trial 10981/22023: the dummy run.
    Hurkmans CW; Borger JH; Rutgers EJ; van Tienhoven G; ;
    Radiother Oncol; 2003 Sep; 68(3):233-40. PubMed ID: 13129630
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Accelerated hyperfractionated simultaneous radiochemotherapy in advanced head-neck carcinomas in comparison: split course and concomitant boost concept].
    Dietz A; Rudat V; Nollert J; Flentje M; Maiei H; Wannenmacher M; Weidauer H
    Laryngorhinootologie; 1996 Dec; 75(12):745-53. PubMed ID: 9081280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of EORTC target definition guidelines for dose-intensified salvage radiation therapy for recurrent prostate cancer: results of the quality assurance program of the randomized trial SAKK 09/10.
    Sassowsky M; Gut P; Hölscher T; Hildebrandt G; Müller AC; Najafi Y; Kohler G; Kranzbühler H; Guckenberger M; Zwahlen DR; Azinwi NC; Plasswilm L; Takacs I; Reuter C; Sumila M; Manser P; Ost P; Böhmer D; Pilop C; Aebersold DM; Ghadjar P
    Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):534-41. PubMed ID: 23972722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dosimetry audit for a multi-centre IMRT head and neck trial.
    Clark CH; Hansen VN; Chantler H; Edwards C; James HV; Webster G; Miles EA; Guerrero Urbano MT; Bhide SA; Bidmead AM; Nutting CM;
    Radiother Oncol; 2009 Oct; 93(1):102-8. PubMed ID: 19596158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality assurance of the SCOPE 1 trial in oesophageal radiotherapy.
    Wills L; Maggs R; Lewis G; Jones G; Nixon L; Staffurth J; Crosby T;
    Radiat Oncol; 2017 Nov; 12(1):179. PubMed ID: 29141663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postoperative radiotherapy with concurrent cisplatin appears to improve locoregional control of advanced, resectable head and neck cancers: RTOG 88-24.
    Al-Sarraf M; Pajak TF; Byhardt RW; Beitler JJ; Salter MM; Cooper JS
    Int J Radiat Oncol Biol Phys; 1997 Mar; 37(4):777-82. PubMed ID: 9128951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality assurance in the 22991 EORTC ROG trial in localized prostate cancer: dummy run and individual case review.
    Matzinger O; Poortmans P; Giraud JY; Maingon P; Budiharto T; van den Bergh AC; Davis JB; Musat E; Ataman F; Huyskens DP; Gulyban A; Bolla M;
    Radiother Oncol; 2009 Mar; 90(3):285-90. PubMed ID: 19038468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of tumor control and presence of visible necrosis in head and neck cancer patients treated with radiotherapy or radiochemotherapy.
    Kuhnt T; Mueller AC; Pelz T; Haensgen G; Bloching M; Koesling S; Schubert J; Dunst J
    J Cancer Res Clin Oncol; 2005 Nov; 131(11):758-64. PubMed ID: 16088405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome impact and cost-effectiveness of quality assurance for radiotherapy planned for the EORTC 22071-24071 prospective study for head and neck cancer.
    Weber DC; Hurkmans CW; Melidis C; Budach W; Langendijk JH; Peters LJ; Grégoire V; Maingon P; Combescure C
    Radiother Oncol; 2014 Jun; 111(3):393-9. PubMed ID: 24861631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02.
    Peters LJ; O'Sullivan B; Giralt J; Fitzgerald TJ; Trotti A; Bernier J; Bourhis J; Yuen K; Fisher R; Rischin D
    J Clin Oncol; 2010 Jun; 28(18):2996-3001. PubMed ID: 20479390
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant cisplatin and radiotherapy in a conventional and modified fractionation schedule in locally advanced head and neck cancer: a randomised phase II EORTC trial.
    Bartelink H; Van den Bogaert W; Horiot JC; Jager J; van Glabbeke M
    Eur J Cancer; 2002 Mar; 38(5):667-73. PubMed ID: 11916549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.